-
公开(公告)号：US20180360828A9
公开(公告)日：2018-12-20
申请号：US15884044
申请日：2018-01-30
发明人： Lloyd F. Mackenzie , Thomas B. MacRury , Curtis Harwig , David Bogucki , Jeffery R. Raymond , Jeremy D. Pettigrew , Vladimir Khlebnikov , Rudong Shan
IPC分类号： A61K31/4965 , A61K31/496 , A61K31/444 , A61K31/443 , A61K31/10 , A61K31/4465 , A61K31/4406 , A61K31/155 , A61K31/495 , A61K31/4196 , A61K31/4164 , A61K31/4402 , A61K31/166 , A61K31/095 , A61K31/277 , A61K31/165 , A61K31/167 , A61K31/09 , A61K31/192 , A61K31/05 , A61K31/085 , A61K31/135 , A61K31/122 , A61K31/12 , A61K31/4439
CPC分类号： A61K31/4965 , A61K31/05 , A61K31/085 , A61K31/09 , A61K31/095 , A61K31/10 , A61K31/12 , A61K31/122 , A61K31/135 , A61K31/155 , A61K31/165 , A61K31/166 , A61K31/167 , A61K31/192 , A61K31/277 , A61K31/4164 , A61K31/4196 , A61K31/4402 , A61K31/4406 , A61K31/443 , A61K31/4439 , A61K31/444 , A61K31/4465 , A61K31/495 , A61K31/496 , C07B2200/07 , C07C39/17 , C07C43/21 , C07C43/215 , C07C43/23 , C07C49/83 , C07C49/835 , C07C49/84 , C07C62/32 , C07C62/34 , C07C217/84 , C07C225/20 , C07C233/26 , C07C233/28 , C07C233/31 , C07C233/32 , C07C233/60 , C07C233/76 , C07C235/82 , C07C237/08 , C07C255/47 , C07C275/26 , C07C275/64 , C07C279/16 , C07C311/07 , C07C311/17 , C07C311/18 , C07C317/22 , C07C323/20 , C07C2602/28 , C07D211/66 , C07D213/38 , C07D213/75 , C07D213/81 , C07D213/82 , C07D213/89 , C07D233/64 , C07D241/24 , C07D249/08 , C07D295/112 , C07D295/215 , C07D401/12 , C07D405/12
摘要： Compounds of formula (I): where n, R1, R4a, R4b, R5, R7 and R8 are defined herein, or pharmaceutically acceptable salts thereof, are described herein. The disclosed compounds have activity as SHIP1 modulators, and thus may be used to treat any of a variety of diseases, disorders or conditions that would benefit from SHIP1 modulation. Compositions comprising a compound of formula (I) in combination with a pharmaceutically acceptable carrier or diluent are also disclosed, as are methods of SHIP1 modulation by administration of such compounds to an animal in need thereof.
-
公开(公告)号：US10077245B2
公开(公告)日：2018-09-18
申请号：US15306971
申请日：2015-04-22
发明人： Fajun Nan , Min Li , Zhaobing Gao , Yangming Zhang , Haining Hu , Haiyan Xu , Huanan Liu , Xiaoping Pi
IPC分类号： C07C235/16 , C07C271/28 , C07D307/24 , A61K31/167 , A61K31/17 , A61K31/27 , A61K31/277 , A61K31/341 , C07C269/04 , C07C269/06 , C07C273/18 , C07C275/64 , C07C231/02 , C07C333/08 , C07C233/62 , C07C235/74 , C07C237/04 , C07C237/22 , C07C237/48
CPC分类号： C07D307/24 , A61K31/167 , A61K31/17 , A61K31/27 , A61K31/277 , A61K31/341 , C07C231/02 , C07C233/62 , C07C235/16 , C07C235/74 , C07C237/04 , C07C237/22 , C07C237/48 , C07C269/04 , C07C269/06 , C07C271/28 , C07C273/18 , C07C275/64 , C07C333/08 , C07C2601/02 , C07C2601/14
摘要： The present invention provides a compound represented by general formula I or a pharmaceutical acceptable salt thereof, the preparation method therefor and the use thereof in preparing a medicine for treating a neurological disease, such as epilepsy, convulsion, neuropathic pain, acute ischemic stroke, and a neurodegenerative disease. The compound according to present invention has a better absorption in brain tissue when compared with RTG. In addition, the compound provided by present invention has not only a greatly enhanced efficacy, but also a neurotoxicity greatly lower than that of RTG, and thus possesses a wider safety window.
-
公开(公告)号：US20180161324A1
公开(公告)日：2018-06-14
申请号：US15884044
申请日：2018-01-30
发明人： Lloyd F. Mackenzie , Thomas B. MacRury , Curtis Harwig , David Bogucki , Jeffery R. Raymond , Jeremy D. Pettigrew , Vladimir Khlebnikov , Rudong Shan
IPC分类号： A61K31/4965 , A61K31/496 , A61K31/444 , A61K31/443 , A61K31/10 , A61K31/4465 , A61K31/4406 , A61K31/155 , A61K31/495 , A61K31/4196 , A61K31/4164 , A61K31/4402 , A61K31/166 , A61K31/095 , A61K31/277 , A61K31/165 , A61K31/167 , A61K31/09 , A61K31/192 , A61K31/05 , A61K31/085 , A61K31/135 , A61K31/122 , A61K31/12 , A61K31/4439
CPC分类号： A61K31/4965 , A61K31/05 , A61K31/085 , A61K31/09 , A61K31/095 , A61K31/10 , A61K31/12 , A61K31/122 , A61K31/135 , A61K31/155 , A61K31/165 , A61K31/166 , A61K31/167 , A61K31/192 , A61K31/277 , A61K31/4164 , A61K31/4196 , A61K31/4402 , A61K31/4406 , A61K31/443 , A61K31/4439 , A61K31/444 , A61K31/4465 , A61K31/495 , A61K31/496 , C07B2200/07 , C07C39/17 , C07C43/21 , C07C43/215 , C07C43/23 , C07C49/83 , C07C49/835 , C07C49/84 , C07C62/32 , C07C62/34 , C07C217/84 , C07C225/20 , C07C233/26 , C07C233/28 , C07C233/31 , C07C233/32 , C07C233/60 , C07C233/76 , C07C235/82 , C07C237/08 , C07C255/47 , C07C275/26 , C07C275/64 , C07C279/16 , C07C311/07 , C07C311/17 , C07C311/18 , C07C317/22 , C07C323/20 , C07C2602/28 , C07D211/66 , C07D213/38 , C07D213/75 , C07D213/81 , C07D213/82 , C07D213/89 , C07D233/64 , C07D241/24 , C07D249/08 , C07D295/112 , C07D295/215 , C07D401/12 , C07D405/12
摘要： Compounds of formula (I): where n, R1, R4a, R4b, R5, R7 and R8 are defined herein, or pharmaceutically acceptable salts thereof, are described herein. The disclosed compounds have activity as SHIP1 modulators, and thus may be used to treat any of a variety of diseases, disorders or conditions that would benefit from SHIP1 modulation. Compositions comprising a compound of formula (I) in combination with a pharmaceutically acceptable carrier or diluent are also disclosed, as are methods of SHIP1 modulation by administration of such compounds to an animal in need thereof.
-
4.发明申请公开(公告)号：US20170081301A1
公开(公告)日：2017-03-23
申请号：US15306971
申请日：2015-04-22
发明人： Fajun NAN , Min LI , Zhaobing GAO , Yangming ZHANG , Haining HU , Haiyan XU , Huanan LIU , Xiaoping PI
IPC分类号： C07D307/24 , C07C237/48 , C07C275/64 , C07C235/16 , C07C271/28 , C07C333/08
CPC分类号： C07D307/24 , A61K31/167 , A61K31/17 , A61K31/27 , A61K31/277 , A61K31/341 , C07C231/02 , C07C233/62 , C07C235/16 , C07C235/74 , C07C237/04 , C07C237/22 , C07C237/48 , C07C269/04 , C07C269/06 , C07C271/28 , C07C273/18 , C07C275/64 , C07C333/08 , C07C2601/02 , C07C2601/14
摘要： The present invention provides a compound represented by general formula I or a pharmaceutical acceptable salt thereof, the preparation method therefor and the use thereof in preparing a medicine for treating a neurological disease, such as epilepsy, convulsion, neuropathic pain, acute ischemic stroke, and a neurodegenerative disease. The compound according to present invention has a better absorption in brain tissue when compared with RTG. In addition, the compound provided by present invention has not only a greatly enhanced efficacy, but also a neurotoxicity greatly lower than that of RTG, and thus possesses a wider safety window.
-
5.发明申请MULTI-TARGETED UBENIMEX PRODRUG DERIVATIVE AND PREPARATION METHOD AND USE THEREOF 有权多目标UBENIMEX PRODRUG衍生和制备方法及其应用公开(公告)号：US20160193347A1
公开(公告)日：2016-07-07
申请号：US14762084
申请日：2014-06-06
发明人： Wenfang Xu , Yuqi Jiang , Yingjie Zhang , Mingming Zou , Jinning Hou , Jin Li , Xuejian Wang , Xiaoyang Li
IPC分类号： A61K47/48 , A61K31/198 , A61K31/506 , A61K31/17 , A61K31/704 , A61K31/513 , A61K38/05
CPC分类号： A61K47/55 , A61K31/17 , A61K31/198 , A61K31/506 , A61K31/513 , A61K31/553 , A61K31/704 , A61K38/05 , C07C275/64 , C07D239/553 , C07D309/14 , C07D417/12
摘要： The present invention relates to the design, synthesis, and biological study of multi-targeted Ubenimex pro-drug derivative. More particularly, provided in the present invention is a compound as shown by general structural formula (I) (wherein the definition of R is shown in the description). The derivative is a multi-targeted compound obtained by binding an aminopeptidase (APN/CD13) inhibitor, Ubenimex, with some anti-tumor drugs already on the market through an ester bond or amide bond, and is suitable for use as an anti-tumor drug for the treating various malignant tumors, and is especially suitable for treating various solid tumors.
摘要翻译： 本发明涉及多靶向Ubenimex前药衍生物的设计，合成和生物学研究。 更具体地，本发明提供的是通式（I）所示的化合物（其中R的定义在说明书中示出）。 该衍生物是通过将氨基肽酶（APN / CD13）抑制剂Ubenimex与已经在市场上已经通过酯键或酰胺键的一些抗肿瘤药物结合获得的多靶向化合物，并且适合用作抗肿瘤 用于治疗各种恶性肿瘤的药物，并且特别适用于治疗各种实体瘤。
-
公开(公告)号：US20150336935A1
公开(公告)日：2015-11-26
申请号：US14759622
申请日：2014-01-07
发明人： Lloyd F. MACKENZIE , Thomas B. MACRURY , Curtis HARWIG , David BOGUCKI , Jeffery R. RAYMOND , Jeremy D. PETTIGREW , Vladimir KHLEBNIKOV , Rudong SHAN
IPC分类号： C07D405/12 , C07C49/835 , C07C225/20 , C07C43/215 , C07C43/23 , C07C39/17 , C07C62/34 , C07C62/32 , C07C233/60 , C07C233/32 , C07C255/47 , C07C323/20 , C07C233/76 , C07D241/24 , C07D213/81 , C07D233/64 , C07D249/08 , C07D295/112 , C07D213/75 , C07C275/26 , C07C275/64 , C07D295/215 , C07D211/66 , C07C317/22 , C07C279/16 , C07C311/07 , C07C311/18 , C07D401/12 , C07C49/84
CPC分类号： A61K31/4965 , A61K31/05 , A61K31/085 , A61K31/09 , A61K31/095 , A61K31/10 , A61K31/12 , A61K31/122 , A61K31/135 , A61K31/155 , A61K31/165 , A61K31/166 , A61K31/167 , A61K31/192 , A61K31/277 , A61K31/4164 , A61K31/4196 , A61K31/4402 , A61K31/4406 , A61K31/443 , A61K31/4439 , A61K31/444 , A61K31/4465 , A61K31/495 , A61K31/496 , C07B2200/07 , C07C39/17 , C07C43/21 , C07C43/215 , C07C43/23 , C07C49/83 , C07C49/835 , C07C49/84 , C07C62/32 , C07C62/34 , C07C217/84 , C07C225/20 , C07C233/26 , C07C233/28 , C07C233/31 , C07C233/32 , C07C233/60 , C07C233/76 , C07C235/82 , C07C237/08 , C07C255/47 , C07C275/26 , C07C275/64 , C07C279/16 , C07C311/07 , C07C311/17 , C07C311/18 , C07C317/22 , C07C323/20 , C07C2602/28 , C07D211/66 , C07D213/38 , C07D213/75 , C07D213/81 , C07D213/82 , C07D213/89 , C07D233/64 , C07D241/24 , C07D249/08 , C07D295/112 , C07D295/215 , C07D401/12 , C07D405/12
摘要： Compounds of formula (I): where, n, R1, R4a, R4b, R5, R7 and R8 are defined herein, or pharmaceutically acceptable salts thereof, are described herein. The disclosed compounds have activity as SHIP1 modulators, and thus may be used to treat any of a variety of diseases, disorders or conditions that would benefit from SHIP1 modulation. Compositions comprising a compound of formula (I) in combination with a pharmaceutically acceptable carrier or diluent are also disclosed, as are methods of SHIP1 modulation by administration of such compounds to an animal in need thereof.
摘要翻译： 本文描述式（I）的化合物：其中，n，R1，R4a，R4b，R5，R7和R8如本文所定义，或其药学上可接受的盐。 所公开的化合物具有作为SHIP1调节剂的活性，因此可用于治疗将受益于SHIP1调节的各种疾病，障碍或病症中的任何一种。 还公开了包含式（I）化合物与药学上可接受的载体或稀释剂的组合物，以及通过将这些化合物施用于有此需要的动物的SHIP1调节方法。
-
公开(公告)号：US20150203448A1
公开(公告)日：2015-07-23
申请号：US14676921
申请日：2015-04-02
IPC分类号： C07C275/64 , C07D213/54 , C07D211/60 , C07D253/065 , C07D307/42 , C07D241/12 , C07D239/26 , A01N47/30 , C07D333/16
CPC分类号： C07C275/64 , A01N47/28 , A01N47/30 , A01N47/32 , A01N47/34 , A61K31/17 , A61K31/197 , A61K31/216 , A61K31/277 , A61K31/341 , A61K31/381 , A61K31/41 , A61K31/415 , A61K31/4196 , A61K31/42 , A61K31/421 , A61K31/4245 , A61K31/426 , A61K31/44 , A61K31/4402 , A61K31/4406 , A61K31/4409 , A61K31/4412 , A61K31/4418 , A61K31/4439 , A61K31/4453 , A61K31/47 , A61K31/4709 , A61K31/4725 , A61K31/4965 , A61K31/498 , A61K31/50 , A61K31/505 , A61K31/506 , A61K31/53 , C07C271/40 , C07C317/22 , C07C381/10 , C07C2601/02 , C07C2601/08 , C07C2601/14 , C07C2601/16 , C07C2602/08 , C07C2602/10 , C07D211/60 , C07D213/30 , C07D213/40 , C07D213/54 , C07D213/61 , C07D213/62 , C07D213/64 , C07D213/74 , C07D213/75 , C07D213/79 , C07D213/83 , C07D213/84 , C07D213/89 , C07D215/20 , C07D215/22 , C07D217/22 , C07D231/12 , C07D237/08 , C07D239/26 , C07D241/12 , C07D249/08 , C07D253/06 , C07D253/065 , C07D257/04 , C07D261/08 , C07D263/10 , C07D271/06 , C07D277/28 , C07D295/16 , C07D295/192 , C07D307/42 , C07D307/52 , C07D333/16 , C07D333/20 , C07D401/12 , C07D417/12
摘要： The present invention provides a pest control agent, acaricide or fungicide that contains, as the active ingredient thereof, at least one type of compound selected from the aryloxyurea compounds represented by formula (V) (wherein R1 to R5 each independently represents an alkyl group or the like, X is a halogen atom or the like, n is an integer of 0 to 5, and Z is an oxygen atom or sulfur atom) or salts thereof
摘要翻译： 本发明提供一种害虫防治剂，杀螨剂或杀真菌剂，其含有选自式（Ⅴ）表示的芳氧基脲化合物中的至少一种化合物（其中R 1至R 5各自独立地表示烷基或 X为卤素原子等，n为0〜5的整数，Z为氧原子或硫原子）或其盐
-
公开(公告)号：US08841276B2
公开(公告)日：2014-09-23
申请号：US13970639
申请日：2013-08-20
发明人： Jack L. Arbiser
IPC分类号： A01N43/04 , A61K31/70 , C09B7/02 , C07D407/04 , C07D233/58 , C07C13/58 , C07D471/10 , A61K31/573 , C07C35/32 , C07D307/58 , C07C39/23 , C07D295/03 , C07C275/64 , C07D209/14 , C07C211/50 , C07C13/40 , C07C13/28 , C07C233/44 , C07D233/68 , A61K31/045 , C07D311/60 , A61K31/341 , C07D209/86 , C07C237/26 , C07D261/08 , C07C69/608 , A61K31/444 , C07C25/18 , A61K31/403 , C07C251/28 , C07D309/38 , A61K31/4164 , C07D311/82 , A61K31/015 , A61K31/5375 , C07D209/82 , C07C215/46 , C07D213/53 , C07C13/66 , C07C43/215 , C07D295/135 , C07C13/465 , C07D277/40 , A61K31/167 , C07C43/23 , C07D473/34 , A61K31/357 , C07D311/58
CPC分类号： C07D209/14 , A61K31/015 , A61K31/045 , A61K31/167 , A61K31/341 , A61K31/357 , A61K31/403 , A61K31/4164 , A61K31/444 , A61K31/5375 , A61K31/573 , C07C13/28 , C07C13/40 , C07C13/465 , C07C13/58 , C07C13/66 , C07C25/18 , C07C35/32 , C07C39/23 , C07C43/215 , C07C43/23 , C07C69/608 , C07C211/50 , C07C215/46 , C07C233/44 , C07C237/26 , C07C251/28 , C07C275/64 , C07C2601/10 , C07C2602/08 , C07C2602/42 , C07C2603/24 , C07C2603/40 , C07C2603/46 , C07D209/82 , C07D209/86 , C07D213/53 , C07D233/58 , C07D233/68 , C07D261/08 , C07D277/40 , C07D295/03 , C07D295/135 , C07D307/58 , C07D309/38 , C07D311/58 , C07D311/60 , C07D311/82 , C07D407/04 , C07D471/10 , C07D473/34
摘要： Compounds, pharmaceutical compositions including the compounds, and methods of preparation and use thereof are disclosed. The compounds are fulvene and/or fulvalene analogs. The compounds and compositions can be used to treat and/or prevent a wide variety of cancers, including drug resistant cancers, as well as numerous inflammatory, degenerative and vascular diseases, including various ocular diseases. Representative fulvene and/or fulvalene analogs include fulvene and fulvalene analogs of various dyes, hormones, sugars, peptides, oligonucleotides, amino acids, nucleotides, nucleosides, and polyols. The compounds are believed to function, at least, by inhibiting Nox or ROS. In some embodiments, the Nox is one that is selectively expressed in cancer cells over normal cells, or one that is expressed in higher amounts in cancer cells over normal cells. Thus, the compounds are novel therapeutic agents for a variety of cancers and other diseases.
摘要翻译： 公开了化合物，包括该化合物的药物组合物，及其制备和使用方法。 化合物是富烯和/或富瓦烯类似物。 化合物和组合物可用于治疗和/或预防多种癌症，包括耐药性癌症，以及许多炎性，退行性和血管性疾病，包括各种眼部疾病。 代表性的富烯和/或富瓦烯类似物包括各种染料，激素，糖，肽，寡核苷酸，氨基酸，核苷酸，核苷和多元醇的富烯和富瓦烯类似物。 据信这些化合物至少通过抑制Nox或ROS起作用。 在一些实施方案中，Nox是在癌细胞中在正常细胞上选择性表达的，或在癌细胞中以比正常细胞更高量表达的那些。 因此，这些化合物是用于各种癌症和其它疾病的新型治疗剂。
-
9.发明申请公开(公告)号：US20100311980A1
公开(公告)日：2010-12-09
申请号：US12677195
申请日：2008-09-10
IPC分类号： C07D213/81 , C07C275/64 , C07C275/34
CPC分类号： C07C271/58 , C07C233/15 , C07C275/30 , C07C275/34 , C07C275/64 , C07D213/81
摘要： There is provided a process for preparing sorafenib or a salt thereof comprising the use of a compound of formula (A) wherein R′ is selected from the group consisting of hydrogen, —C(O)OA, —C(O)CX3, —C(O)NH2, —C(O)—NHOH or There is also provided intermediate compounds of general formula (A), N-methyl-4-(4-ureidophenoxy)picolinamide, 4-(2-(methylcarbamoyl)pyridin-4-yloxy)phenylcarbamate derivative and N-methyl-4-(4-(2,2,2-trihaloacetamido)phenoxy)picolinamide, processes for their preparation and their use in the preparation of sorafenib.
摘要翻译： 提供了制备索拉非尼或其盐的方法，其包括使用式（A）化合物，其中R'选自氢，-C（O）OA，-C（O）CX 3， - C（O）NH 2，-C（O）-NHOH或还提供通式（A）的中间体化合物，N-甲基-4-（4-脲基苯氧基）吡啶酰胺，4-（2-（甲基氨基甲酰基） （4-（2,2,2-三卤代乙酰氨基）苯氧基）吡啶甲酰胺，其制备方法及其在制备索拉非尼中的用途。
-
10.发明申请METHOD OF ENHANCING CELLULAR PRODUCTION OF MOLECULAR CHAPERONE, HYDROXYLAMINE DERIVATIVES USEFUL FOR ENHANCING THE CHAPERONE PRODUCTION AND THE PREPARATION THEREOF 审中-公开增强分子量酮的生产方法，有助于增强CHAPERONE生产的羟基衍生物及其制备方法公开(公告)号：US20100267711A1
公开(公告)日：2010-10-21
申请号：US12823823
申请日：2010-06-25
申请人： László Vígh , Péter Literáti Nagy , Jenó Szilbereky , László Ürögdi , Andrea Jednákovits , László Jaszlits , Katalin Bíró , Ede Màrvànyos , Mihály Barabás , Erzsébet Hegedüs , László Korányi , Mária Kürthy , Gábor Balogh , Ibolya Horváth , Zsolt Török , Éva Udvardy , György Dormán , Dénes Medzihradszky , Bea Mézes , Eszter Kovács , Ernó Duda , Beatrix Farkas , Attila Glatz
发明人： László Vígh , Péter Literáti Nagy , Jenó Szilbereky , László Ürögdi , Andrea Jednákovits , László Jaszlits , Katalin Bíró , Ede Màrvànyos , Mihály Barabás , Erzsébet Hegedüs , László Korányi , Mária Kürthy , Gábor Balogh , Ibolya Horváth , Zsolt Török , Éva Udvardy , György Dormán , Dénes Medzihradszky , Bea Mézes , Eszter Kovács , Ernó Duda , Beatrix Farkas , Attila Glatz
IPC分类号： A61K31/5395 , C07D273/04 , C12N5/02 , A61P31/04 , A61P31/12 , A61P35/00 , A61P9/10 , C12N5/071
CPC分类号： C07D213/78 , C07C259/02 , C07C259/18 , C07C275/64 , C07C279/18 , C07C2601/14 , C07D213/89 , C07D215/54 , C07D217/26 , C07D295/088 , C07D307/68 , C07D333/38 , C07D409/12 , C07D413/04
摘要： A method of increasing expression of a molecular chaperon by a cell and/or enhancing the activity of a molecular chaperon in cells is provided. The method comprises treating a cell that is exposed to a physiological stress which induces expression of a molecular chaperon by the cell with an effective amount of a certain hydroxylamine derivative to increase the stress. Alternatively, an hydroxylamine derivative can be administrated to a cell before it is exposed to a physiological stress which induces expression of a molecular chaperon by the cell. Preferably, the cell to which an hydroxylamine derivative is administered is an eukaryotic cell. The hydroxylamine derivative corresponds to the formulae (I) or (II).The invention also provides novel hydroxylamine derivatives falling within the scope of the formulae (I) and (II) as well as pharmaceutical and/or cosmetical compositions comprising the said compounds.
摘要翻译： 提供了增加细胞分子伴侣表达和/或提高细胞中分子伴侣活性的方法。 所述方法包括用有效量的某种羟胺衍生物处理暴露于生理应激的细胞，所述生理应激诱导细胞表达分子伴侣以增加应激。 或者，可以在细胞暴露于诱导细胞分子伴侣表达的生理应激之前向细胞施用羟胺衍生物。 优选地，施用羟胺衍生物的细胞是真核细胞。 羟胺衍生物对应于式（I）或（II）。 本发明还提供了落入式（I）和（II）范围内的新型羟胺衍生物以及包含所述化合物的药物和/或化妆品组合物。
-
-
-
-
-
-
-
-
-
搜索结果
264 条记录 (耗时 0.049 秒)
